-
Innovation Ranking
NewInnovation Ranking – Vaxart Inc
Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a...
-
Company Insights
Innovation and Patenting activity of Vaxart Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vaxart Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewNet Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Empower your strategies with our Net Present Value Model: Vaxart Inc's Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VXAG-1.1NN in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VXAG-1.1NN in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VXAG-1.1NN in Norovirus Infections Drug Details: VXAG-1.1NN is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Vulvar Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Vulvar Cancer Drug Details: AGEN-2373 is under development for the...
-
Product Insights
Genital Herpes – Drugs In Development, 2023
Global Markets Direct’s, ‘Genital Herpes - Drugs In Development, 2023’, provides an overview of the Genital Herpes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Norovirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Norovirus Infections - Drugs In Development, 2023’, provides an overview of the Norovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Norovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chikungunya Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Chikungunya Fever - Drugs In Development, 2023’, provides an overview of the Chikungunya Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2023’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...